|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.023 AUD | 0.00% |
|
-20.69% | -4.17% |
| Apr. 29 | AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs | MT |
| Apr. 08 | AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market | MT |
AdAlta Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 1.11 million compared to AUD 0.727268 million a year ago. Net loss was AUD 2.82 million compared to AUD 3.66 million a year ago.
Basic loss per share from continuing operations was AUD 0.009 compared to AUD 0.0148 a year ago. Diluted loss per share from continuing operations was AUD 0.009 compared to AUD 0.0148 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.17% | 8.09M | |
| +3.91% | 108B | |
| +10.87% | 104B | |
| +1.28% | 22.33B | |
| -13.14% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.66% | 17.64B | |
| +3.75% | 14.05B | |
| +36.70% | 12.51B |
ADALTA LIMITED 